Always prioritize safety and work closely with healthcare professionals when exploring peptide therapies
More information can be found under referral procedures.
Key values to watch during this period include electrolytes, especially sodium and potassium, kidney function markers, and fasting glucose if applicable
[2] The Phase 3a REDEFINE 2 trial then tested once-weekly CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) against placebo in 1,206 adults with obesity and type 2 diabetes over 68 weeks, reporting a mean bodyweight change of 13.7% versus 3.4% for placebo
Additionally, tirzepatide may affect how quickly alcohol is absorbed due to delayed gastric emptying, potentially altering your tolerance
Even minor changes in warfarin levels can lead to serious clotting or bleeding problems, underscoring the importance of regular monitoring when taking GLP-1 medications